CorteseIMuranskiPEnose-AkahataY, et al. Pembrolizumab treatment for progressive multifocal leukoencephalopathy. Engl J Med2019; 380(17): 1597–1605.
2.
ColtartHEl BouzidiKMulkaL, et al. Marked clinical and radiological improvement following pembrolizumab therapy for HIV-associated PML-IRIS. AIDS2023; 37(1): 199–200.
3.
DarcySAlexanderMMcCarthyA, et al. Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: A report of two cases. J Neurovirol2022; 28(1): 145–150.
4.
BarrittAWDasEMorleyN, et al. Management approach including pembrolizumab for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing-remitting multiple sclerosis. Mult Scler2023; 29(2): 301–306.
5.
HoPRKoendgenHCampbellN, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: A retrospective analysis of data from four clinical studies. Lancet Neurol2017; 16(11): 925–933.
6.
MorrowSACliftFDevonshireV, et al. Use of natalizumab in persons with multiple sclerosis: 2022 update. Mult Scler Relat Disord2022; 65: 103995.
